Cannara Biotech (LOVFF) announced its intention to settle an aggregate of approximately $6.2M of indebtedness, consisting of $4.7M in principal and approximately $1.5M in accrued interest, under its convertible debenture issued to Olymbec Investments and subsequently amended on August 31, 2023, January 30, 2024, and February 21. The Olymbec Convertible Debenture was originally issued in the total principal amount of $5.7M. As previously disclosed on June 18, 2025, the Company repaid $1M, thereby reducing the outstanding principal to $4.7M. The Company proposes to satisfy the outstanding indebtedness through the issuance of 3,462,763 common shares of Cannara, 851,652 of which represent the repayment of interest owing, at a deemed issuance price of $1.80 per Common Share, in accordance with the terms of the Olymbec Convertible Debenture.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LOVFF:
- Cannara Biotech Grants Incentive Awards Amid Growth
- Cannara Biotech Expands Credit Facility to Boost Production Capacity
- Cannara Biotech announces amendment, upsize of BMO credit facility
- Cannara Biotech Boosts Financial Flexibility with Strategic Asset Sale
- Cannara Biotech completes sales of non-core building for $5.5M in proceeds